menu search

PTGX / FDA Intends To Revoke Protagonist Therapeutics' Rusfertide Breakthrough Tag In Rare Form Of Blood Cancer

FDA Intends To Revoke Protagonist Therapeutics' Rusfertide Breakthrough Tag In Rare Form Of Blood Cancer
Protagonist Therapeutics Inc (NASDAQ: PTGX) received a letter from the FDA indicating the agency's intent to rescind Breakthrough Therapy Designation for the company's rusfertide product candidate in polycythemia vera.  Polycythemia vera is a type of blood cancer. Read More
Posted: Apr 14 2022, 06:33
Author Name: Benzinga
Views: 103173

PTGX News  

Protagonist Therapeutics to Present at Upcoming Investor Conferences

By Accesswire
September 5, 2023

Protagonist Therapeutics to Present at Upcoming Investor Conferences

NEWARK, CA / ACCESSWIRE / September 5, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dines more_horizontal

Protagonist Therapeutics: Evaluating Rusfertide's Potential For PV

By Seeking Alpha
September 4, 2023

Protagonist Therapeutics: Evaluating Rusfertide's Potential For PV

Protagonist Therapeutics focuses on peptide-based drugs, primarily rusfertide, which is undergoing a Phase 3 trial for polycythemia vera. Financially, more_horizontal

Protagonist Therapeutics (PTGX) Is a Great Choice for 'Trend' Investors, Here's Why

By Zacks Investment Research
June 30, 2023

Protagonist Therapeutics (PTGX) Is a Great Choice for 'Trend' Investors, Here's Why

Protagonist Therapeutics (PTGX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit more_horizontal

Wall Street Analysts Predict a 25.35% Upside in Protagonist Therapeutics (PTGX): Here's What You Should Know

By Zacks Investment Research
June 15, 2023

Wall Street Analysts Predict a 25.35% Upside in Protagonist Therapeutics (PTGX): Here's What You Should Know

The consensus price target hints at a 25.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-afte more_horizontal

Here's Why Momentum in Protagonist Therapeutics (PTGX) Should Keep going

By Zacks Investment Research
June 13, 2023

Here's Why Momentum in Protagonist Therapeutics (PTGX) Should Keep going

Protagonist Therapeutics (PTGX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit more_horizontal

How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 38.01%

By Zacks Investment Research
May 26, 2023

How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 38.01%

The average of price targets set by Wall Street analysts indicates a potential upside of 38% in Protagonist Therapeutics (PTGX). While the effectivene more_horizontal

Protagonist Therapeutics Sees Steady If Bumpy Progress

By Seeking Alpha
May 25, 2023

Protagonist Therapeutics Sees Steady If Bumpy Progress

The stock of Protagonist Therapeutics, Inc. has more than doubled so far this year due to progress on a couple of fronts. Can the rally in the shares more_horizontal

Protagonist Therapeutics: All Quiet Heading Into An Important H2 2023

By Seeking Alpha
May 24, 2023

Protagonist Therapeutics: All Quiet Heading Into An Important H2 2023

Protagonist continues to quietly progress its pipeline, relying mainly on the polycythemia vera story to drive its business efforts. An ongoing phase more_horizontal


Search within

Pages Search Results: